40岁及以下视网膜中央静脉阻塞相关黄斑水肿患者的玻璃体内抗血管内皮生长因子注射治疗
Intravitreal Anti-Vascular Endothelial Growth Factor Injections for Macular Edema Associated With Central Retinal Vein Occlusion in Patients Age 40 Years or Younger.
作者信息
Gao Xinxiao, Obeid Anthony, Aderman Christopher M, Ali Ferhina S, Vander James F, Hsu Jason, Ho Allen C
出版信息
Ophthalmic Surg Lasers Imaging Retina. 2019 Apr 1;50(4):e96-e104. doi: 10.3928/23258160-20190401-13.
BACKGROUND AND OBJECTIVE
To determine the efficacy of anti-vascular endothelial growth factor (VEGF) therapy for macular edema due to central retinal vein occlusion (CRVO) in younger adults.
PATIENTS AND METHODS
The outcomes of CRVO patients age 40 years or younger with baseline logarithm of the minimum angle of resolution (logMAR) visual acuity (VA) between 1.30 (20/400 Snellen equivalent) and 0.30 (20/40 Snellen equivalent) and central retinal thickness (CRT) greater than 250 μm were reviewed. VA and CRT were measured at baseline and months 1, 3, 6, and 12.
RESULTS
Seventeen eyes of 17 young CRVO patients were included in this study. The logMAR VA improved significantly from 0.64 (20/87 Snellen equivalent) to 0.14 (20/28 Snellen equivalent) 12 months following treatments (P < .001). The CRT decreased from 619 μm ± 238 μm at baseline to 290 μm ± 34 μm at 12 months (P < .001).
CONCLUSION
Anti-VEGF injections appear to be effective for macular edema regression and vision improvement in younger adults with CRVO over 12 months of follow-up. [Ophthalmic Surg Lasers Imaging Retina. 2019;50:e96-e104.].
背景与目的
确定抗血管内皮生长因子（VEGF）疗法对年轻成年人中心性视网膜静脉阻塞（CRVO）所致黄斑水肿的疗效。
患者与方法
回顾性分析年龄40岁及以下、基线最小分辨角对数（logMAR）视力（VA）在1.30（相当于Snellen视力表20/400）至0.30（相当于Snellen视力表20/40）之间且中心视网膜厚度（CRT）大于250μm的CRVO患者的治疗结果。在基线以及第1、3、6和12个月测量VA和CRT。
结果
本研究纳入了17例年轻CRVO患者的17只眼。治疗12个月后，logMAR VA从0.64（相当于Snellen视力表20/87）显著改善至0.14（相当于Snellen视力表20/28）（P <.001）。CRT从基线时的619μm±238μm降至12个月时的290μm±34μm（P <.001）。
结论
在12个月的随访中，抗VEGF注射似乎对年轻CRVO患者的黄斑水肿消退和视力改善有效。[《眼科手术、激光与视网膜成像》。2019；50：e96 - e104。]
Zotero 插件